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as Biphasic or Sarcomatoid Mesothelioma
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Introduction: In patients with epithelioid diffuse malignant pleural
mesothelioma (DMPM), clinical stage is the current primary prog-
nostic factor. We sought to investigate whether histologic subtyping
can prognostically stratify patients with epithelioid DMPM.
Methods: Hematoxylin and eosin-stained slides of 232 patients with
epithelioid DMPM (14 stage I, 54 stage II, 130 stage III, and 34
stage IV) from a single institution were reviewed. We classified the
tumors into five subtypes, according to the predominant histological
pattern: trabecular, tubulopapillary, micropapillary, solid, and pleo-
morphic (10% of tumor).
Results: Median overall survival (OS) of all patients with epitheli-
oid DMPM was 16.2 months. Patients with pleomorphic subtype
(n  34) had the worst median OS (8.1 months), followed by solid
(n  89, 13.7 months), micropapillary (n  20, 15.8 months),
tubulopapillary (n  51, 17.9 months), and trabecular (n  38, 24.9
months). The pleomorphic subtype was associated with lymphatic
and vascular invasion (p  0.001). The micropapillary subtype was
associated with lymphatic invasion (p  0.001). In univariate
analyses, pleomorphic subtype was significantly associated with
poor OS (p  0.003). The pleomorphic subtype showed no signif-
icant difference on OS compared with biphasic and sarcomatoid
DMPM. In a multivariate analysis, the pleomorphic subtype was an
independent predictor of poor OS (p  0.031). In patients who
underwent R1 resection, pleomorphic subtype had the shortest
median time to recurrence (13.7 months).
Conclusion: Our finding that the pleomorphic subtype is a predictor
of aggressive behavior in epithelioid DMPM with no survival
difference from biphasic or sarcomatoid DMPM suggests that it may
be best regarded as a sarcomatoid pattern rather than a subtype of
epithelioid DMPM.
Key Words: Epithelioid mesothelioma, Pleomorphic, Micropapil-
lary, Lymphatic invasion, Survival.
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Diffuse malignant pleural mesothelioma (DMPM) is themost common primary malignancy of the pleura, but it
poses both a diagnostic and clinical challenge due to its
heterogeneity in histology1,2 and clinical outcome.3,4 Cur-
rently, therapeutic decisions are dictated mainly by histologic
type and the tumor, node, metastasis (TNM) staging system.
The utility of the TNM staging, however, is limited to
stratifying early (I–II) from late-stage patients (III–IV).5 His-
tologically, DMPM is classified into three main types, epi-
thelioid, biphasic, and sarcomatoid,6 and epithelioid DMPM
is the most common histologic type and has the best prog-
nosis.2,3,5,7–9 Despite the known wide spectrum of histology
in epithelioid DMPM, no comprehensive study has estab-
lished clinical significance of histologic subtypes within ep-
ithelioid DMPM. Histologic subtyping has shown significant
associations with clinicopathologic features in adenocarcino-
mas of several other organs, such as lung,10,11 breast,12,13 and
gastric cancer.14,15 Especially in lung adenocarcinoma, we
and others have reported that histologic subtypes show asso-
ciations with prognosis as well as molecular and genetic
features.10,11
To this end, we sought to correlate the histologic
subtypes of epithelioid DMPM with clinicopathologic fea-
tures and further investigate the biological association with
morphology. We herein report a comprehensive pathologic
review of 232 epithelioid DMPM from a single institution to
better understand DMPM biology and patient outcome.
PATIENTS AND METHODS
Patients
Information on 305 patients diagnosed with DMPM
between 1989 and 2009 at Memorial Sloan-Kettering Cancer
Center was collected through the Thoracic Surgery mesothe-
lioma database and the Department of Pathology data file.
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Internal review board approval was obtained for this study.
Pathologic diagnosis was based on standard histologic, his-
tochemical, and immunohistochemical criteria.6,16–18 As a
positive marker of immunohistochemistry for DMPM, we
used calretinin, WT-1, cytokeratin 5/6, and D2-40. As nega-
tive markers for DMPM, we used carcinoembryonic antigen,
CD15, B72.3, BerEP4, and thyroid transcription factor-1. In
cases before positive mesothelial markers were available,
negative markers were used for making the diagnosis of
DMPM. In addition, the pathology findings were correlated
with the gross distribution of tumor and absence of an
intrapulmonary mass lesion or radiologic features of a pri-
mary lung carcinoma.
Review of pathological reports and confirmation by two
pathologists (K.K. and W.D.T) yielded 232 epithelioid, 47
biphasic, and 26 sarcomatoid DMPM. Variables recorded in
the database included age, gender, laterality, T status, N
status, TNM stage, and surgical procedure. TNM staging was
based on the reported imaging findings, the surgeon’s intra-
operative findings, and the pathologic evaluation of the re-
sected specimens using the sixth edition of the American
Joint Commission on Cancer staging manual.19 All patients
were followed until date of death or date of last follow-up.
Histologic Evaluation
Two pathologists (K.K. and W.D.T.) reviewed all
available hematoxylin and eosin-stained slides of epithelioid
DMPM, which included a median nine slides per case (range:
1–43). Histologic classification for epithelioid DMPM was
done according to the 2004 World Health Organization
(WHO) criteria (10% sarcomatoid component).6 Tumors
comprised one or more of the following five histological
subtypes, which were recorded in 5% increments: trabecular,
tubulopapillary, micropapillary, solid, and pleomorphic. Tu-
mors were classified as pleomorphic subtype when cytologic
pleomorphism comprised at least 10% of the tumor, similar to
the diagnosis of pleomorphic carcinoma of the lung.6 The
remaining tumors were classified according to the predomi-
nant histologic component (trabecular, tubulopapillary, mi-
cropapillary, or solid subtype).
The trabecular pattern was composed of relatively
small, uniform cells arranged in thin cords, sometimes in a
single file arrangement (Figure 1A).20 The tubulopapillary
subtype showed varying combinations of tubules and papil-
lary structures that are lined by relatively bland, flat, cuboi-
dal, or polygonal tumor cells (Figure 1B).1,6 Some tubules
had a cribriform (so-called adenoid cystic) pattern that we
included in the tubulopapillary subtype. The micropapillary
pattern was defined as papillary structures with tufts lack-
ing a central fibrovascular core (Figure 1C).11,21 The solid
pattern consists of sheets or nests of polygonal to round
tumor cells, lacking any specific morphologic arrangement
or pleomorphism (Figure 1D).1,6 Tumors with anaplastic or
prominent giant cells were designated as pleomorphic
features (Figure 1E).1,6 Tumor cells in the pleomorphic
pattern showed nuclear enlargement, hyperchromasia,
prominent nucleoli, and some multinucleation. Pleomor-
phism was evaluated only in the area where tumor cells
clearly showed epithelioid morphology.
FIGURE 1. Histologic subtypes of epithelioid diffuse malignant pleural mesothelioma (DMPM) (hematoxylin and eosin [H&E]
stain; original magnification, 200: A, B, C, and D and 400: E). A, Trabecular subtype is composed of relatively small, uni-
form cells infiltrating in thin cord arrangement. B, Tubulopapillary subtype exhibits varying combinations of tubules and papil-
lary structures lined by relatively bland flat, cuboidal, or polygonal tumor cells. C, Micropapillary subtype was defined as papil-
lary structures with tufts lacking a central fibrovascular core. D, Solid subtype consists of sheets or nests of polygonal to round
tumor cells. E, Pleomorphic subtype is composed of anaplastic or prominent giant cells.
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In addition to the five histologic subtypes, the following
four cytologic features were evaluated and considered posi-
tive if present in at least 10% of the tumor: microcystic
(so-called adenomatoid pattern), clear cell, deciduoid, and
small cell.20 One stromal feature, myxoid change, was eval-
uated and considered positive if myxoid stroma occupied
more than 50% of the tumor volume, as defined previously in
another study.22 Histologically, the microcystic feature was
composed of relatively small cystic structures formed by
flattened and cuboidal cells. The clear cell feature is com-
posed of cells that have clear cytoplasm, resembling clear cell
carcinoma of the kidney. The deciduoid feature is composed
of cells that resemble progestationally stimulated endometrial
stromal cells or cells seen in placental tissue. The small cell
feature closely resembles small cell carcinoma of the lung.20
Finally, presence of lymphatic and vascular invasion was also
noted if at least one tumor cell cluster was visible in a
lymphatic vessel or vein, respectively.
Statistical Analysis
For patients with epithelioid DMPM, associations be-
tween clinicopathologic variables and histologic subtype
were analyzed using Fisher’s exact test for categorical vari-
ables and Wilcoxon test for continuous variables. Overall
survival (OS) after surgery was estimated using the Kaplan-
Meier method, with patients censored if they were alive at the
time of last follow-up. An analysis of time to recurrence
(TTR) was restricted to patients with R1 resection. Nonpara-
metric group comparisons were performed using log-rank test
adjusted for stage.23 Multivariate analyses were performed
using the Cox proportional hazard regression model to study
the effects of different variables on OS. All p values were
based on two-tailed statistical analysis, and a p value less than
0.05 was considered to indicate statistical significance. All
analysis was performed using SAS statistical software (ver-
sion 8.02; SAS Institute Inc., Cary, NC).
RESULTS
Demographics
The clinicopathologic profile of the patients with epi-
thelioid DMPM is outlined in Table 1. There were 232
patients with a median age 64 years (range: 29–85 years),
72% of which were men. The tumor involved the left pleura
in 45% of the cases and the right in 55%. Fourteen (6%) of
the patients were stage I, 54 (23%) were stage II, 130 (56%)
were stage III, and 34 (15%) were stage IV. By procedure,
115 (50%) underwent extrapleural pneumonectomy, 91
(39%) pleurectomy decortication, and the remaining 26
(11%) had other procedures, including 11 biopsies, 10 ex-
ploratory thoracotomies, three palliative pleurectomies, and
two video-assisted thoracoscopic surgeries.
TABLE 1. Clinicopathologic Factors by Five Histologic Subtypes in 232 Patients with Epithelioid DMPM
All Patients Histologic Subtype (%)
No. Percentage TRB TUP MIP SOL PLM p
All patients 232 100 16 22 9 38 15
Age (yr)
Median (range) 64 (29–85) 63 (44–78) 63 (29–79) 67 (31–76) 62 (29–85) 67 (35–81) 0.550
Gender
Female 64 28 34 31 40 24 18 0.295
Male 168 72 66 69 60 76 82
Laterality
Left 104 45 37 39 50 51 44 0.554
Right 128 55 63 61 50 49 56
T status
T1–T2 108 47 55 49 50 46 32 0.390
T3–T4 124 53 45 51 50 54 68
N status
N0 139 60 71 65 35 60 56 0.017
N1–N3 93 40 29 35 65 40 44
Stage
I–II 68 29 45 29 15 29 21 0.110
III–IV 164 71 55 71 85 71 79
Ly invasion
Absent 130 56 92 71 5 53 32 0.001
Present 102 44 8 29 95 47 68
V invasion
Absent 178 77 100 90 70 74 41 0.001
Present 54 23 0 10 30 26 59
TRB, trabecular; TUP, tubulopapillary; MIP, micropapillary; SOL, solid; PLM, pleomorphic; Ly, lymphatic; V, vascular; DMPM, diffuse malignant pleural mesothelioma.
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Associations between Histologic Subtypes and
Clinicopathologic Factors
The most common histologic subtype was solid (n 
89, 38%), followed by tubulopapillary (n  51, 22%), tra-
becular (n  38, 16%), pleomorphic (n  34, 15%), and
micropapillary (n  20, 9%). Associations between histo-
logic subtypes and clinicopathologic features are outlined in
Table 1. Lymph node metastases were detected in 40% of all
cases and seen more frequently in the micropapillary subtype
(65%) (p  0.017). Lymphatic invasion was detected in 44%
of cases and was associated with the micropapillary (95%)
and pleomorphic (68%) subtypes (p  0.001). In contrast,
trabecular and tubulopapillary subtypes were associated with
less lymphatic invasion (8% and 29%, respectively). More-
over, lymphatic invasion showed a strong association with
lymph node metastasis (p  0.001). Vascular invasion was
detected in 23% of cases and was more frequently observed
among patients with the pleomorphic subtype (59%, p 
0.001). In contrast, trabecular and tubulopapillary subtypes
were associated with less vascular invasion (0% and 10%,
respectively). No association was found between histologic
subtype and age, gender, laterality, T status, or stage.
Associations between Histologic Subtype
and OS
Among all stages patients with epithelioid DMPM,
median OS was 16.2 months, with a 2-year OS of 34% and
5-year OS of 11%. On univariate analyses, older age (age
65 years) (p  0.046), right-sided disease (p  0.040),
advanced stage (stages III–IV) (p  0.007), lymphatic inva-
sion (p  0.001), and vascular invasion (p  0.001) were
associated with poor OS (Table 2). When we analyzed the
survival association by morphology, patients with the pleo-
morphic subtype had a significantly worse OS (8.1 months)
compared with patients with solid (13.7 months, p  0.020),
micropapillary (15.8 months, p  0.021), tubulopapillary
(17.9 months, p  0.002), and trabecular subtypes (24.9
months, p  0.001) (Figure 2A). In 68 early-stage patients
(stages I–II), patients with pleomorphic (n  7) and micro-
papillary (n  3) subtypes had a significantly worse median
TABLE 2. Univariate Analysis in Predicting Overall Survival in Patients with Epithelioid DMPM
Variables
All Stages Stage III
No. Median OS (95% CI) p No. Median OS (95% CI) p
All patients 232 16.2 (14.6–19.0) 130 14.4 (9.4–17.4)
Age (yr)
65 132 17.9 (14.7–22.0) 0.046 75 14.5 (9.5–20.4) 0.196
65 100 15.0 (11.2–17.5) 55 12.3 (8.2–17.5)
Gender
Female 64 20.8 (17.4–32.5) 0.065 34 19.1 (9.8–32.5) 0.171
Male 168 14.9 (12.3–17.4) 96 12.0 (8.9–16.9)
Laterality
Left 104 17.4 (14.5–25.0) 0.040 61 17.4 (12.3–28.7) 0.012
Right 128 15.0 (12.4–19.0) 69 9.5 (7.5–16.7)
Stage
I–II 68 19.4 (16.3–31.0) 0.007 NA NA NA
III–IV 164 14.4 (9.8–17.4) NA NA
Lymphatic invasion
Absent 130 21.6 (17.9–26.6) 0.001 56 24.9 (17.5–36.5) 0.001
Present 102 11.2 (8.5–15.0) 74 8.9 (7.3–12.0)
Vascular invasion
Absent 178 18.1 (16.2–21.9) 0.001 89 17.4 (14.5–21.9) 0.006
Present 54 8.9 (7.1–14.6) 41 8.2 (5.4–12.3)
Histologic subtypes
Trabecular 38 24.9 (22.9–39.9) 0.001 15 28.7 (20.2–NR) 0.001
Tubulopapillary 51 17.9 (14.4–32.5) 0.002 30 16.2 (9.4–29.1) 0.003
Micropapillary 20 15.8 (9.3–45.3) 0.021 15 15.0 (6.2–NR) 0.028
Solid 89 13.7 (10.0–16.9) 0.020 51 11.2 (8.5–19.9) 0.010
Pleomorphic 34 8.1 (4.9–17.0) Ref. 19 4.9 (4.1–17.4) Ref.
Surgical procedure
EPP 115 13.2 (9.5–17.4) 0.472 78 9.4 (7.5–14.5) 0.452
PD 91 18.9 (16.9–24.9) 44 17.8 (15.0–26.6)
Others procedures 26 14.8 (7.7–37.8) 8 21.1 (14.8–NR)
OS, overall survival; NA, not applicable; NR, not reached; EPP, extrapleural pneumonectomy; PD, pleurectomy/decortication; CI, confidence interval; DMPM, diffuse malignant
pleural mesothelioma.
Journal of Thoracic Oncology • Volume 6, Number 5, May 2011 Pleomorphic Epithelioid DMPM
Copyright © 2011 by the International Association for the Study of Lung Cancer 899
OS (14.7 months and 15.0 months, respectively), compared
with trabecular (n  17, 26.3 months, p  0.001 and 0.010,
respectively) and tubulopapillary (n  15, 33.7 months, p 
0.001 and 0.020, respectively) subtypes (Figure 2B). Similar
observations were made in the 130 stage III patients, the most
common stage in our series (Figure 2C).
A multivariate analysis confirmed that pleomorphic
subtype was an independent predictor of worse OS, after
controlling for age, laterality, stage, lymphatic, and vascular
invasions (Table 3). Specifically, compared with the pleomor-
phic group, the risk of death was reduced by 49% in the
trabecular group, by 50% in the tubulopapillary group, by
58% in the micropapillary group, and by 33% in the solid
group. In addition, right-sided disease (hazard ratio [HR] 
1.46, 95% confidence interval [CI]: 1.09–1.97), advanced
stage (HR  1.56, 95% CI: 1.12–2.18), and lymphatic inva-
sion (HR  1.52, 95% CI: 1.07–2.16) were also indepen-
dently associated with increased risk of death.
We further compared prognosis among patients with
epithelioid, biphasic, and sarcomatoid DMPM. Epithelioid
DMPM (n  232) had a better OS (16.2 months) compared
with the biphasic group (n  47, 7.0 months) and the
sarcomatoid (n  26, 3.8 months) (p  0.001) (Figure 3A).
The pleomorphic subtype (8.1 months) showed no significant
difference in OS compared with biphasic (p  0.96) and
sarcomatoid DMPM (p  0.15) (Figure 3B). On the basis
of this observation, we performed a survival analysis in the
epithelioid DMPM excluding the pleomorphic subtype.
When we combined the trabecular and the tubulopapillary
subtype (n  89), this group had a significantly better OS
(23.3 months) compared with the solid subtype (13.7
months, p  0.026) (Figure 4) and when compared with
the combined solid/micropapillary group (n  109, 14.7
months, p  0.026).
As for other cytologic features, microcystic pattern was
detected in 43 (18.5%) patients; however, this was not asso-
ciated with prognosis. Other features such as clear cell,
deciduoid, and small cell pattern were only identified in a
FIGURE 2. Overall survival by five
histologic subtypes in patients with
epithelioid diffuse malignant pleural
mesothelioma (DMPM). Patients with
the pleomorphic subtype had signifi-
cantly worse overall survival (A) in 232
all-stage patients (8.1 months), (B) in
68 early-stage (stages I–II) patients
(14.7 months), and (C) in 130 stage
III patients (4.9 months).
TABLE 3. Multivariate Analysis in Predicting Overall Survival
in 232 Patients with Epithelioid DMPM
Variables Hazard Ratio 95% CI p
Age (65 vs. 65) 1.32 0.99–1.76 0.056
Laterality (right vs. left) 1.46 1.09–1.97 0.012
Stage (III–IV vs. I–II) 1.56 1.12–2.18 0.009
Lymphatic invasion 1.52 1.07–2.16 0.019
Vascular invasion 1.23 0.80–1.88 0.340
Morphology (overall) 0.031
Pleomorphic 1.00 Ref. Ref.
Trabecular vs. pleomorphic 0.51 0.29–0.91 0.022
Tubulopapillary vs. pleomorphic 0.50 0.30–0.85 0.010
Micropapillary vs. pleomorphic 0.42 0.22–0.78 0.006
Solid vs. pleomorphic 0.67 0.43–1.05 0.077
CI, confidence interval; DMPM, diffuse malignant pleural mesothelioma.
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very few cases (3.0%, 6.9%, and 6.5%, respectively). Stromal
myxoid change was detected in 18 (8%) patients in our series,
and it was not associated with prognosis.
Associations between Histologic Subtype and
TTR
Among 159 patients who underwent R1 resection, pa-
tients with the pleomorphic subtype (n 22) had the shortest
median TTR (13.7 months), although the difference was only
significant when compared with the tubulopapillary (n  39,
23.6 months, p 0.041) and trabecular (n 21, 67.2 months,
p  0.043) subtypes (Figure 5). Similar observations were
made in 53 stage I to stage II patients. Moreover, in 99 stage
III patients, patients with pleomorphic (n  15, 13.7 months)
and solid subtypes (n  37, 15.7 months) had significantly
shorter median TTR compared with patients with trabecular
(n  8, 67.0 months, p  0.020 and 0.020, respectively) and
tubulopapillary subtypes (n  26, 23.6 months, p  0.030
and 0.030, respectively). We further compared TTR among
patients with epithelioid, biphasic, and sarcomatoid DMPM.
Although the median TTR was 21.8 months in epithelioid
without pleomorphic subtype patients (n 137), 13.7 months
in pleomorphic (n  22), 13.5 months in biphasic (n  32),
and 31.8 in sarcomatoid (n  13), there was no significant
difference (p  0.226).
DISCUSSION
The 2004 WHO classification defines three main his-
tologic types of DMPM—epithelioid, biphasic, and sarcoma-
toid.6 Nevertheless, there is a great diversity of histologic
patterns within these three main histologic types, and some
DMPMmay show multiple histologic patterns.1,24 To the best
of our knowledge, however, there are no established associ-
ations between the histologic patterns of epithelioid DMPM
and clinical outcome. The importance of recognizing these
patterns has been mostly for the purpose of making an
accurate diagnosis and histologic differentiation between
DMPM and other neoplasms.1 Especially in epithelioid
DMPM, many histologic patterns have been reported, such as
tubulopapillary, adenomatoid (also termed microcystic),
solid, glandular, clear cell, deciduoid, adenoid cystic, signet
ring, and small cell pattern.1,6,20
In our study, we evaluated five histologic subtypes
(tubulopapillary, trabecular, solid, micropapillary, and pleo-
FIGURE 3. Overall survival by histo-
logic type (epithelioid, biphasic, and
sarcomatoid) in 305 patients with dif-
fuse malignant pleural mesothelioma
(DMPM). (A) Patients with epithelioid
DMPM had a significantly better me-
dian survival (16.2 months) compared
with biphasic (7.0 months) and sarco-
matoid (3.8 months). (B) The pleo-
morphic subtype (8.1 months)
showed no significant difference on
overall survival compared with bipha-
sic and sarcomatoid DMPM.
FIGURE 4. Overall survival by combined group with histo-
logic subtypes in 232 all-stage patients with epithelioid dif-
fuse malignant pleural mesothelioma (DMPM). Patients with
trabecular and tubulopapillary combined group had signifi-
cantly better overall survival (23.3 months) compared with
the solid subtype (13.7 months).
FIGURE 5. Time to recurrence by five histologic subtypes
in 159 patients who underwent R1 resection. Patients with
pleomorphic subtype had the shortest median time to recur-
rence (13.7 months).
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morphic), four cytologic features (microcystic, clear cell,
deciduoid, and small cell), and one stromal feature, myxoid.
Although a pleomorphic pattern of malignant mesothelioma
has been previously recognized, and it is defined in the 2004
WHO Classification as a subtype of epithelioid DMPM,6
there are little data defining the clinical characteristics of
these tumors. In lung cancer, pleomorphic carcinomas are
defined as a non-small cell lung carcinoma (NSCLC) that has
a component of at least 10% spindle and/or giant cells.6
Mochizuki et al.25 reported that vascular invasion was signif-
icantly more common in the pleomorphic carcinoma patients
than in other patients with NSCLC. Moreover, the 5-year
survival rate and median survival time of pleomorphic carci-
noma patients were significantly lower than in other patients
with NSCLC. In DMPM, Galateau-Salle et al.26 recently
reported in an abstract that median survival of 44 patients
with DMPM with pleomorphic feature was 7 months com-
pared with 13 months for patients with conventional (non-
pleomorphic) epithelioid mesothelioma. Their result is in
concordance with our results. In our study, there were 34
patients with pleomorphic subtype (15%), who experi-
enced the worst median OS (8.1 months), and pleomorphic
subtype was an independent poor prognostic factor. In
addition, pleomorphic subtype had a near identical OS
curve as biphasic DMPM and did not show a significant
difference in OS compared with sarcomatoid DMPM. This
finding suggests that the pleomorphic subtype, currently
classified as epithelioid DMPM by the 2004 WHO Clas-
sification,6 should be regarded as a sarcomatoid pattern
and the tumors reclassified as biphasic or sarcomatoid
DMPM, depending on whether the pleomorphic/sarcoma-
toid component is 10% or greater. This is an approach
similar to pleomorphic carcinoma of the lung in which the
presence of 10% spindle and/or giant cells has such a
significant adverse impact on survival that these tumors are
reclassified under the general category of sarcomatoid
carcinoma.
The tubulopapillary DMPM has been previously de-
scribed by Johansson and Linde´n,27 who showed in their
series of 85 patients that those with exclusively tubulopapil-
lary DMPM had a significantly prolonged median survival
compared with other subtypes. Nevertheless, their study also
included biphasic and sarcomatoid DMPM, thus failing to
show a true survival advantage of tubulopapillary over non-
tubulopapillary only within the category of epithelioid
DMPM alone. In our study, patients with tubulopapillary
subtype showed longer OS (17.9 months) than other subtypes
although the evidence was only conclusive when compared
with the pleomorphic subtype. Cerruto et al.28 showed in 62
malignant peritoneal mesotheliomas that the solid pattern
showed a worse median survival than the tubulopapillary
counterpart. In our study, patients with solid subtype had
significantly a worse median OS compared with the com-
bined trabecular and tubulopapillary group.
The micropapillary pattern, when found in carcinomas
of breast,29,30 lung,31 urinary bladder,32 colorectal,33,34 and
parotid grand,35 is associated with significantly shorter sur-
vival and tendency to present with extensive lymph node and
distant metastasis. It is rarely reported in DMPM.21,36 Mogi et
al.21 reported a micropapillary component in 2 of 34 DMPM
(5.9%), and these cases showed significantly more lymphatic
invasion, pulmonary metastasis, and a trend toward more
lymph node involvement compared with those without a
micropapillary component. In our series, 20 cases (9%) out of
232 patients with epithelioid DMPM were micropapillary
predominant. Similar to Mogi et al., we found a significant
association with lymphatic invasion. In addition, we also
showed that the micropapillary subtype correlates with more
frequent lymph node metastases, which is associated with
poor OS in DMPM.4,37–39 The patients with micropapillary
subtype had a median OS of 15.8 months, which was shorter,
but not significantly worse, compared with tubulopapillary
(17.9 months) and trabecular subtype (24.9 months). Further-
more, this difference was more pronounced in stage I to stage
II patients, suggesting that micropapillary subtype is a nega-
tive prognostic marker in early stage, which is similar to what
is observed in lung adenocarcinoma.31
For the four tumor features—microcystic, clear cell,
deciduoid, and small cell—we could not demonstrate any
association with prognosis although this negative finding
could be due to small number of cases. Also, although Shia et
al.22 previously reported 19 cases of DMPM with myxoid
stroma, who experienced a prolonged median survival of 36
months, we did not observe a significant difference in OS in
our 18 cases.
Disease recurrence has been an important clinical prob-
lem after surgical resection in DMPM. Positive microscopic
margin has been known as a poor prognostic factor in several
series.4,40 In our study, patients who underwent R1 resection
(microscopic involvement of surgical resection margins) with
pleomorphic subtype had the shortest median TTR. More
impressive is the fact that in 99 stage III patients who
underwent R1 resection, patients with pleomorphic (13.7
months) and solid subtypes (15.7 months) had significantly
shorter median TTR compared with patients with trabecular
(67.0 months) and tubulopapillary subtypes (23.6 months).
In conclusion, we have shown that histologic subtyping
in epithelioid DMPM is associated with tumor biology and
clinical outcome. Based on our findings, the pleomorphic
subtype is associated with aggressive clinical and biologic
behavior such as very poor prognosis, rapid recurrence, and
prominent lymphatic and vascular invasion; therefore, we
propose that it is best regarded as a sarcomatoid pattern rather
than an epithelioid one. This should be considered with future
revision of the WHO Classification of DMPM. If the pleo-
morphic tumors are excluded from the epithelioid DMPM
category and reclassified as biphasic or sarcomatoid types,
the main subtypes of epithelioid DMPM would be trabecular,
tubulopapillary, micropapillary, and solid. Then the solid and
micropapillary epithelioid DMPM would be high-grade sub-
types: the solid subtype showed an unfavorable OS compared
with patients with trabecular and tubulopapillary combined
group and a high preponderance for recurrence, and the
micropapillary subtype was a marker of poor prognosis in
early stage and was frequently associated with lymphatic and
vascular invasions. In contrast, the trabecular and tubulopap-
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illary subtypes would be considered as low-grade histological
subtypes, based on a favorable clinical behavior.
In recent years, several attempts have been made to
develop a better prognostic system for epithelioid DMPM to
allow physicians to appropriately communicate the prognosis
to patients and further stratify patients for clinical trials.
Anatomically, Richards et al.41 proposed an adjustment to the
current TNM staging to better reflect clinical outcome. Ra-
diographically, Nowak et al.42 showed that a prognostic
model using quantitative positron emission tomography-fluo-
rodeoxyglucose was more predictive of survival than TNM
staging in nonsarcomatoid DMPM. Genetically, several
genes43–46 and micro-RNA47 have been identified as potential
prognostic markers. Our comprehensive histologic subtyping
of epithelioid DMPM suggests that histology is an important
prognostic marker and should be incorporated into future
studies investigating clinical, molecular, genetic, and radio-
graphic findings. Translation of our findings in reclassifying
DMPM by histological characteristics is practical and imme-
diately available at all institutions.
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